Summary LexaGene has just started sales of a revolutionary automated PCR machine that can test for 27 pathogens at once in about one hour.
It parallels Electrovaya, which have a recent 15 bagger on, a value nanocap stock in a highly favored sector that is likely to go profitable and have extreme growth.
I can find nothing wrong with the company as the management, market, technology and execution are all excellent.
Timing is perfect, they have just started sales with a $billion+ sales potential product and FDA approval to enter the POC market is possible in May.
Now we are up big, with 1.22 high up 22%. That is 3 year new highs, near all time highs blue sky breakout of 1.29
This is an easy stock for people to relate to and understand. It can become a popular stock both with pros and public alike.
Imagine what happens when FDA approves it.
LexaGene’s MiQLab is designed for point-of-care use and for simultaneous screening of numerous respiratory pathogens, including COVID-19 strain identification. The system is open-access, which allows for new tests to be easily loaded onto the system. This is a unique feature that is not found in any other system designed for point-of-care use.
Dr. Jack Regan, LexaGene’s CEO and Founder states, “Just three weeks ago, we designed assays to detect the UK and SA variants to demonstrate proof-of-principle that these assays could be quickly ported onto the MiQLab. ”
News 
Market Data 
Discover 
AI
